Acadia Pharmaceuticals Inc. filed an 8-K on September 11, 2026, disclosing that a U.S. federal court preliminarily approved the proposed settlement of a stockholder derivative lawsuit against the company.

Key Highlights

  • Court approval: The United States District Court for the Southern District of California preliminarily approved the settlement on August 24, 2026.
  • Case name: The action is captioned Kanner et al. v. Biggar et al., Case No. 3:23-cv-02293-WQH-MSB.
  • Notice requirement: The company is required by court order to publish the Notice of Pendency and Proposed Settlement of Derivative Matters.
  • Documents filed: The settlement notice (Exhibit 99.1) and the Stipulation and Agreement of Settlement (Exhibit 99.2) were attached to the filing.
  • Public access: Both documents are available on the Investor Relations section of the company's website at ir.acadia.com.
  • Signed by: Jennifer J. Rhodes, Executive Vice President and Chief Legal Officer, signed the filing on behalf of the company.

Acadia Pharmaceuticals Publishes Court-Mandated Settlement Notice in Derivative Action

According to the filing, the United States District Court for the Southern District of California issued an order on August 24, 2026, granting preliminary approval of the settlement in the stockholder derivative action Kanner et al. v. Biggar et al., Case No. 3:23-cv-02293-WQH-MSB. The filing was made under Item 8.01 (Other Events) of the 8-K form, indicating a disclosure of a significant development not otherwise covered by a specific reporting item.

The filing states that pursuant to the court's preliminary approval order, Acadia Pharmaceuticals Inc. is required to publish the Notice of Pendency and Proposed Settlement of Derivative Matters. The company attached this notice as Exhibit 99.1 and the full Stipulation and Agreement of Settlement as Exhibit 99.2. The filing notes that both documents are available for public review on the Investor Relations section of the company's website at ir.acadia.com.

The 8-K was signed on September 11, 2026, by Jennifer J. Rhodes, identified in the filing as Executive Vice President and Chief Legal Officer of Acadia Pharmaceuticals Inc. (NASDAQ:ACAD). The company is incorporated in Delaware and headquartered at 12830 El Camino Real, Suite 400, San Diego, California 92130. The filing does not include financial statements, as Item 9.01 references only the attached exhibits.

What Was Disclosed

Acadia Pharmaceuticals reported the preliminary court approval of a settlement in a stockholder derivative lawsuit and disclosed its obligation, under the court's order, to publish the settlement notice and stipulation for stockholder review.